Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 14, 2026
TickeronGET DAILY SIGNALS
Merck & Co. (MRK) Maintains Stability with +1.8% Gain Near $147.78

Merck & Co. (MRK) Maintains Stability with +1.8% Gain Near $147.78

Key Takeaways

  • MRK shares traded near $147.78 in mid-November, a modest gain of roughly 1.8% versus the closing price from 30 calendar days earlier, reflecting a stable rather than volatile stretch.
  • Third-quarter 2026 revenue rose 5% year over year to $18.1 billion, led by Keytruda, Winrevair, Gardasil, and the Animal Health segment.
  • Management raised and narrowed full-year 2026 guidance to revenue of $66.8 billion to $67.3 billion and adjusted EPS of $2.77 to $2.82, signaling growing near-term confidence.
  • The central investment narrative remains the company's effort to diversify beyond Keytruda, whose U.S. patent exclusivity begins to lapse in 2028.
  • Late-stage pipeline momentum, including positive Phase 3 data for the sac-TMT antibody-drug conjugate and the individualized neoantigen therapy with MRNA, has reinforced long-term growth expectations.
  • Investors can review additional details on Price Targets, Earnings, and Forecast pages to assess the stock's broader outlook.
  • For automated, data-driven perspectives on MRK and thousands of other tickers, explore Trending AI Robots.

Current Market Snapshot

MRK has traded within a relatively contained range in recent weeks, holding in the mid-to-high $140s. The stock's roughly 1.8% advance over the trailing 30 days contrasts with the sharper double-digit swings seen earlier in the year, suggesting investors are weighing near-term commercial strength against the longer-term challenge of the upcoming Keytruda loss of exclusivity. The shares were trading near $147.78 as of mid-November, with the prior session's close at $147.76.

Sentiment has been broadly constructive following a third-quarter earnings report that topped expectations and raised guidance, though the stock has not broken decisively into new territory. Within the large-cap pharmaceutical group, MRK continues to be followed closely as a bellwether for oncology franchise durability and pipeline execution.

Merck & Co. (MRK) Business Overview and Competitive Position

Merck & Co., Inc., based in Rahway, New Jersey, is a global healthcare company that develops and markets prescription medicines, vaccines, biologic therapies, and animal health products. Its portfolio is anchored by Keytruda (pembrolizumab), one of the world's leading oncology immunotherapies, along with the HPV vaccine franchise Gardasil, the pulmonary arterial hypertension treatment Winrevair, and the Animal Health business.

The company's competitive strength rests on a broad late-stage pipeline spanning oncology, immunology, cardiometabolic disease, respiratory medicine, and ophthalmology. Investors follow MRK not only for its current commercial performance but also for how effectively it transitions toward newer products ahead of Keytruda's expected U.S. patent expiry in 2028. Management has emphasized a strategy of internal pipeline advancement combined with targeted acquisitions to reduce dependence on a single product.

Recent Developments Driving MRK

Merck's third-quarter 2026 results, reported on October 29, were a central catalyst. Revenue increased 5% year over year to $18.085 billion, or 4% excluding foreign exchange, driven by oncology growth, newer products, and Animal Health. Non-GAAP earnings per share came in at $2.49, which included a $0.12 charge tied to a licensing agreement with SciBrunch for an investigational oral KRAS G12D inhibitor. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Keytruda sales rose 6% to $8.6 billion, including $830 million from the newly approved subcutaneous formulation Keytruda QLEX. Winrevair sales surged roughly 93% to $694 million, while Gardasil grew about 14% and Animal Health advanced 4%. Management attributed approximately $550 million of quarterly sales to favorable U.S. purchase timing that is expected to unwind in subsequent periods.

The company also raised its full-year outlook. Guidance was narrowed to revenue of $66.8 billion to $67.3 billion and adjusted EPS of $2.77 to $2.82. Looking further ahead, management expects 2027 revenue to grow modestly, with newer products and Animal Health partly offset by more than $2 billion in generic and loss-of-exclusivity headwinds affecting products such as Bridion, the Januvia family, and Adempas.

On the pipeline front, positive Phase 3 data for sac-TMT in advanced or recurrent endometrial cancer supported a U.S. FDA application under priority review, while the individualized neoantigen therapy intismeran, developed with MRNA (Moderna), showed a clinically meaningful reduction in the risk of recurrence or death in resected melanoma. These readouts have strengthened the narrative that Merck can navigate the Keytruda patent cliff.

2026 Outlook and What Investors Should Watch

As 2026 progresses, investors are likely to focus on several key themes. Near-term attention remains on whether Merck can sustain Keytruda, Winrevair, and Gardasil momentum while managing the expected unwinding of purchase-timing benefits in the fourth quarter. The company has guided to full-year revenue growth of 3% to 4% and adjusted EPS of $2.77 to $2.82, figures that anchor current expectations.

Longer term, the pipeline remains the central driver. Regulatory milestones for sac-TMT, potential filing activity for the individualized neoantigen therapy, and additional late-stage readouts across oncology, immunology, and ophthalmology are likely to shape sentiment. Management has pointed to a commercial opportunity exceeding $70 billion from its emerging portfolio by the mid-2030s, a projection that depends on continued clinical and regulatory success.

Key risks include the 2028 loss of exclusivity for Keytruda, competitive pressure in oncology, generic erosion of older products beginning in 2027, pricing and policy changes, and execution risk across a broad development portfolio. Macroeconomic factors such as foreign-exchange movements and interest-rate conditions also influence reported results. Investors should monitor earnings updates, guidance revisions, clinical data releases, and regulatory decisions when assessing the stock's trajectory.

Exploring AI Tools for Additional Perspectives

In my own research process, I often review Tickeron’s Trending AI Robots for quantitative context on names like MRK. The page highlights top-performing automated strategies across different timeframes and risk levels, offering a systematic complement to traditional fundamental analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MRK

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for MRK turns negative, indicating new downward trend

MRK saw its Momentum Indicator move below the 0 level on November 13, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 84 similar instances where the indicator turned negative. In 45 of the 84 cases, the stock moved further down in the following days. The odds of a decline are at 54%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 34 of 52 cases where MRK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.

The Moving Average Convergence Divergence (MACD) for MRK just turned positive on October 30, 2026. Looking at past instances where MRK's MACD turned positive, the stock continued to rise in 25 of 50 cases over the following month. The odds of a continued upward trend are 50%.

MRK moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for MRK crossed bullishly above the 50-day moving average on November 09, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +6.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRK advanced for three days, in 191 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.

The Aroon Indicator entered an Uptrend today. In 172 of 265 cases where MRK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 65%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. MRK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 28 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 79 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.633) is normal, around the industry mean (-1.421). MRK's P/E Ratio (116.452) is considerably higher than the industry average of (21.700). Projected Growth (PEG Ratio) (2.716) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.038) among similar stocks. P/S Ratio (5.402) is also within normal values, averaging (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 7%. MIRA experienced the highest price growth at 16%, while SCLX experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -33%. For the same stocks of the Industry, the average monthly volume growth was -34% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 32
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 17 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of human and animal health products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
126 East Lincoln Avenue
Phone
+1 908 740-4000
Employees
75000
Web
https://www.merck.com
Interact to see
Advertisement
The central price target used here is $400 , roughly 35% above Alphabet's latest verified closing price of $295.77 (November 13, 2026). This target is the arithmetic mean of verified analyst price targets reviewed, not a single analyst's forecast; independent data providers report comparable consensus averages in the high-$390s to low-$400s.
Upcoming catalysts: Integration of advertising into AI Overviews and Gemini conversations, the scaling of Gemini 3 and newer models across Search and Cloud, and the commercial ramp of the $32 billion Wiz cloud-security acquisition could all shape sentiment into 2026. Strategic positioning: Alphabet's vertically integrated artificial intelligence (AI) stack — from custom TPU (Tensor Processing Unit) chips to the Gemini models to Google Cloud — supports a durable, cost-advantaged position in the AI build-out.
The TETH exchange-traded fund (ETF) is the 21Shares Ethereum Staking ETF, a spot Ethereum fund listed on Cboe BZX, and it does not carry conventional analyst price targets. The $14 objective used here is a technical milestone discussed in public market commentary — roughly the zone where Ethereum could begin confirming a recovery — not an analyst consensus.
Alphabet (GOOGL) fell roughly 15.3% over the last 30 days, sliding from about $349.22 to $295.77, driven primarily by a post-earnings selloff. The decline followed Alphabet's Q3 2026 results, when earnings per share of $2.12 badly missed the $3.02 consensus estimate.
The central target of $6.70 is the arithmetic mean of seven recent, individually verified analyst price targets, rounded from $6.67. At a latest price near $3.70, reaching $6.70 would require roughly 81% upside — a very large move.